奥泰生物: 关于向2024年限制性股票激励计划激励对象授予预留部分限制性股票的公告

Core Points - The company has announced the reserved grant of 188,000 restricted stocks under the 2024 Restricted Stock Incentive Plan, with a grant date set for August 29, 2025 [1][2][16] - The grant price for the restricted stocks has been adjusted from 29.24 yuan per share to 26.2993 yuan per share [5][16] - The incentive plan aims to enhance employee cohesion and operational efficiency, potentially leading to improved business performance [18] Summary by Sections Incentive Plan Overview - The 2024 Restricted Stock Incentive Plan has been approved, and the reserved grant conditions have been met [2][16] - A total of 41 individuals will receive the reserved stocks, which represent approximately 0.24% of the company's total share capital [11][16] Grant Conditions and Procedures - The decision-making process for the stock grant has been completed, including necessary disclosures and approvals from the board and supervisory committee [3][4][16] - The company has confirmed that no disqualifying conditions exist for the incentive recipients, ensuring compliance with relevant laws and regulations [6][16] Performance Metrics - The performance assessment for the incentive plan will be conducted over two fiscal years, with specific revenue and product registration targets set for each vesting period [12][15] - The first vesting period requires a revenue target of 1.05 billion yuan, while the second period requires a target of 1.26 billion yuan [12] Accounting and Financial Impact - The fair value of the restricted stocks will be calculated using the Black-Scholes model, and the associated costs will be amortized over the vesting period [18] - The implementation of the incentive plan is expected to have a positive impact on the company's operational performance and internal value [18]